The Comparion of Pregnancy Outcomes between GnRH Agonist and GnRH Antagonist Cycles in Women with Advanced Age.
- Author:
Chan Woo PARK
1
;
Sun Wha CHA
;
Hae Suk KIM
;
Hye Ok KIM
;
Kwang Moon YANG
;
Jin Young KIM
;
In Ok SONG
;
Keun Jae YOO
;
Inn Soo KANG
;
Mi Kyoung KOONG
Author Information
1. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Samsung Cheil Hospital and Women's Healthcare Center, Sungkyunkwan University School of Medicine, Seoul, Korea. novak21c@yahoo.co.kr
- Publication Type:Original Article ; In Vitro
- Keywords:
COH, GnRH antagonist;
GnRH agonist;
Old age
- MeSH:
Azoospermia;
Cardiopulmonary Resuscitation;
Embryo Transfer;
Endometriosis;
Female;
Fertilization in Vitro;
Gonadotropin-Releasing Hormone*;
Gonadotropins;
Humans;
Live Birth;
Oocytes;
Polycystic Ovary Syndrome;
Pregnancy;
Pregnancy Outcome*;
Pregnancy Rate;
Pregnancy*;
Retrospective Studies
- From:Korean Journal of Fertility and Sterility
2005;32(3):261-268
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To compare the clinical results and pregnancy outcomes of in vitro fertilization (IVF) between GnRH antagonist cycles and GnRH agonist (GnRH-a) cycles including flare-up and long protocol in women with advanced age. MATERIALS AND METHODS: Retrospective clinical study. From January 2001 to September 2003, IVF cycles of female patient 37 years over were included in this study. GnRH-a long protocol (62 cycles, 61 patients) and GnRH antagonist multi-dose flexible protocol (66 cycles, 51 patients) were compared with the control group of GnRH-a flare-up protocol (151 cycles, 138 patients). IVF cycles for non-obstructive azoospermia (NOA), endometriosis III, IV and polycystic ovarian syndrome (PCOS) were excluded in this study. Clinical results such as total gonadotropin dose, serum E2 on hCG administration, the number of retrieved oocytes and the pregnancy outcomes - clinical pregnancy rate (CPR), implantation rate (IR) and live birth rate (LBR) per embryo transfer - were compared. RESULTS: There were significant differences in the total dose of gonadotropin (GnRH-a flare-up vs. GnRH-a long vs. GnRH-antagonist; 41.8 vs. 54.7 vs. 24.8), serum E2 on hCG administration (1787.2 vs. 1881.6 vs. 788.0), the numbers of retrieved oocytes (8.1 vs. 11.1 vs. 4.5) and endometrial thickness (9.1 vs. 10.4 vs. 8.0) which were significantly lower in GnRH-antagonist cycles. But pregnancy outcomes shows no significant differenced in CPR (25.0% vs. 35.8% vs. 24.5%), IR (11.7% vs. 12.3% vs. 10.1%) and LBR (15.8% vs. 28.3% vs. 15.1%) CONCLUSION: In women with advanced age, GnRH-antagonist cycles can result in comparable pregnancy outcomes to GnRH-a cycles including flare-up and long protocol. GnRH-a long protocol show higher CPR, IR and LBR than GnRH antagonist multi-dose flexible protocol and flare-up protocol without significant differences.
